Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207948 · ClinicalTrials.gov registry record
Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents
A clinical trial, sponsored by Children's National Research Institute.
- Terminated
- Registry status
- 4
- Enrollment target
NCT00207948 is a clinical trial that was terminated before completion, run by Children's National Research Institute. The registered enrollment target is 4 participants.
The verdict
NCT00207948 was terminated before completion, sponsored by Children's National Research Institute.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This was a feasibility study aimed at elevating protease inhibitors (PI) dosage as a part of active antiretroviral therapy (HAART). After the pharmacokinetics for the currently prescribed PI were determined,patients with a vIQ\<1 were eligible for a 50% dose increase for an 8 week time frame after which their vIQ would be reassessed to determine if increasing their PI dosage thereby increasing the bioavaiability would reduce their viral load.
Interventions
- DRUG Dose adjustment of Kaletra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207948
The ClinicalTrials.gov registry entry for NCT00207948 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dose adjustment of Kaletra is the first listed.
NCT00207948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207948 about?
NCT00207948 is a clinical study titled "Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents". This was a feasibility study aimed at elevating protease inhibitors (PI) dosage as a part of active antiretroviral therapy (HAART). After the pharmacokinetics for the currently prescribed PI were determined,patients with a vIQ\<1 were eligible for a 50% dose increase for an 8 week time frame after w...
What is the current status of trial NCT00207948?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2004-11. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00207948?
The interventions under investigation include: Dose adjustment of Kaletra (DRUG).
Who is sponsoring clinical trial NCT00207948?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.